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Chapter 1 
A novel specific genetic translocation in epithelioid hemangioendothelioma showing a fusion 
of the WWTR1 and CAMTA1 genes. 
 
 
Introduction 
 
Vascular tumors encompass a wide histologic spectrum and include hemangioma, 
hemangioendothelioma, angiosarcoma, and their epithelioid variants (Wenger and Wold,  
2000; O’Connell et al., 2001). The vast majority of both benign and malignant vascular 
tumors are readily diagnosed based on their characteristic histologic features, such as the 
formation of vascular spaces and the expression of endothelial markers. However, some 
vascular tumors have atypical histologic features, such as a solid growth pattern, epithelioid 
change, or spindle cell morphology, which complicates their diagnosis (Folpe et al., 2001). 
For this rare subset of vascular tumors, there remains considerable controversy in regards to 
the terminology and the classification that should be used (O’Connell et al., 2001; Evans et 
al., 2003). For example, Evans et al. (2003) argued that epithelioid hemangioma is not a 
distinct tumor entity but rather a misdiagnosed hemangioendothelioma, a tumor that, unlike 
hemangioma, has metastatic potential. Furthermore, hemangioendothelioma of bone is not 
listed as a distinct diagnostic entity in current classification systems (World Health 
Organization Classification of Tumours, 2002).  
The genetic hallmark of vascular tumors is still under investigation. To date, only a 
few cases of vascular tumors have been analyzed cytogenetically, reporting different 
chromosomal translocations (Boudousquie et al., 1996; He et al., 2006; Dunlap et al., 2009). 
However, Mendlick et al. (2001) found an identical chromosomal translocation involving 
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chromosomes 1 and 3 [t(1;3)(p36.3:q25)] in 2 cases of epithelioid hemangioendothelioma 
(EHE), which possibly represents a characteristic rearrangement for this histopathologic 
entity. Therefore, we undertook a systematic molecular analysis of a large spectrum of EHEs, 
including lesions from various anatomic locations and lesions with different biological 
potentials. We hypothesized that a better understanding of the molecular signature of vascular 
tumors may help to refine the present classification system based on immunophenotype alone.  
 
Material and Methods 
 
We retrieved 23 cases of EHE with tissue samples available for molecular analysis 
from the surgical pathology and consultation files of our institution. In each case, we 
confirmed the pathologic diagnosis and the histologic grade by reviewing the pathology 
slides and by immunostaining them for the following endothelial cell markers: CD31, CD34, 
FLI1, and von Willebrand factor. The tumors were assessed morphologically for growth 
pattern, vasoformative nature, epithelioid versus spindle cell composition, cellular 
pleomorphism, mitotic activity, and necrosis (Fig 1).  
For each case, the location of the tumor was recorded, along with the anatomic 
structures involved. Based on their location, the lesions were classified into 4 groups: bone, 
soft tissue, intrathorax, and liver.  
Because EHE, a low-grade tumor with metastatic potential, is intermediate between 
epithelioid hemangioma, a benign tumor, and epithelioid angiosarcoma, a high-grade 
malignant tumor, we included 15 cases of epithelioid hemangioma and 5 cases of epithelioid 
angiosarcoma to determine if there was any relationship between them. In addition, we 
included 3 cases of epithelioid sarcoma because this tumor has the same morphologic and 
immunophenotypic features as EHE. 
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Fig 1: Morphological appearance of epithelioid vascular tumors analyzed in this study. (A) Malignant EHE of the arm, with 
cords and single cells of epithelioid cells with moderate nuclear atypia, embedded in a hyalinized stroma. (B) Classic EHE of 
the liver with bland epithelioid cells with readly visible intracytoplasmatic vacuoles. (C) EH of the penis in a 48-year-old 
man, who presented as multiple cutaneous and s.c. nodules, and showed large epithelioid cells with abundant eosinophilic 
cytoplasm surrounding vascular lumina. (D) Radiation-induced angiosarcoma of breast, composed of predominantly 
epithelioid morphology and showing high grade cytologic atypia, with prominent nucleoli, as well as vascular channel 
formation. 
 
 
FISH was performed on paraffin-embedded 4-µm-thick tissue sections using custom-
labeled FISH probes, as previously described (Antonescu et al., 2010). Each case was 
analyzed with 3 probes covering and flanking chromosomes 1p36.3 and 3q25. The rearranged 
regions of each chromosome were then evaluated using 3 new probes. This process was 
repeated as much as possible to zoom into the rearranged chromosomal regions (Fig. 2, 3).  
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Fig 2: FISH positional cloning strategy using BAC probe sets on 1p36.33-1p36.11. Three sets of experiments identified the breakpoint in 
1p36.23. Underlined genes have been previously reported in other chromosomal translocations. 
 
 
 
 
 
 
 
 
 
 
Fig 3: Distribution of BAC probe sets tested spanning the 3q24-27 region. Three rounds of FISH experiments illustrated in this diagram 
were able to narrow-down the break-apart region between 3q24-25.1. Underlined genes have been previously reported in other chromosomal 
translocations. 
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FISH enabled us to focus on the 200-kb region in which the CAMTA1 and WWTR1 
genes are located in chromosomes 1 and 3, respectively. Therefore, we performed reverse 
transcriptase-polymerase chain reaction (RT-PCR) on the 3 cases of EHE with frozen tissue 
available using housekeeping primers, as previously described (Antonescu et al., 2010). The 
RT-PCR products were analyzed by electrophoresis, and the RT-PCR-amplified products 
were sequenced using the Sanger method (Antonescu et al., 2010). 
 
Results 
 
In this study, we included a total of 17 cases of immunohistochemically confirmed 
EHE with tissue available for molecular analysis (Table I).  
 
EHE 
Case 
no. 
Age Sex Location IHC WWTR1-
CAMTA1 
Fusion 
Oncological 
Outcome 
Months 
1 52 F Soft Tissue CD 31 and CD 34 + AWD 15 
2 54 M Soft Tissue CD 31 and CD 34 + NED 108 
3 59 F Soft Tissue CD 31 and Factor VIII + NED 116 
4 39 M Soft Tissue CD31, CD34 and FLI1 + NED 14 
5 68 M Soft Tissue CD31 and Factor VIII + NED 16 
6 66 M Soft Tissue CD31 and CD34 + NED 4 
7 39 F Soft Tissue CD31 and CD34 + DOD 43 
8 56 M Intra-thoracic CD31 and CD34 + NED 30 
9 65 F Intra-thoracic CD31 and CD34 + NED 20 
10 61 M Intra-thoracic CD31, CD34 and Factor 
VIII 
+ DOD 82 
11 32 M Intra-thoracic CD34 + AWD 7 
12 29 F Intra-thoracic CD31 and CD34 + Lost at FU ? 
13 42 F Intra-thoracic  + NED 23 
14 34 M Intra-thoracic CD31 + DOD 4 
15 48 F Liver CD31 and CD34 + Lost at FU ? 
16 41 F Liver CD31 and CD34 + NED 7 
17 25 M Bone CD31 + DOD 24 
 
Table I: EHE, epithelioid hemangioendotelioma; NED, no evidence of disease; AWD, alive with disease; DOD, dead of disease; FU, 
follow-up. 
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Six cases were excluded because of unsuccessful fluorescence in situ hybridization 
(FISH): 4 cases because of low cellularity and 2 cases because of decalcification. There were 
8 women and 9 men, with a median age of 48 years (range, 25 to 68 years). The anatomic 
distribution of EHE was as follows: 7 cases in soft tissue, 7 in the intrathorax, 2 in the liver, 
and 1 in bone. 
All cases had an identical chromosomal translocation involving chromosomes 1 and 3 
[t(1;3)(p36.23:q25.1)]. Immunohistochemically, all tumors were positive for CD31, showing 
typically strong and diffuse staining, as well as for CD34 and/or Factor VIII or FLI1. The 
RT-PCR applied in the 3 tumors with available frozen tissue showed 3 different 
rearrangements: fragments of exons 8 and 9 of CAMTA1 were fused in-frame to a fragment 
of exon 2 of WWTR1 (Fig. 4).  
 
Fig. 4: Identification of candidate genes on 1p36.23 and 3q25 by FISH. (A) Gray are showed 1p36.23 breakpoint location within CAMTA1 
gene. Three-color FISH showed a break-apart between green-RP11-1120114 and Orange-RP11-338N10 (inset). (B) Two-color FISH 
(orange-RP11-2G17 and Red-580-RP11-255N4) identified a split red signal associated with the orange signal (inset). This pattern narrowed 
the breakpoint at chr.3: 149270000 (hg. 19), which localized in WWTR1 exon 4 to exon 8. 
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Fig. 5: RT-PCR detection of WWTR1-CAMTA1 fusion transcript variants and FISH demonstration of fused CAMTA1 and WWTR1 
signals. (A) Gel electrophoresis showing amplified products in lanes 1-3, of two distinct sizes (M, size marker, lane 1; EHEs line 1, 2 and 3; 
negative control, lane 4). (B) Sequencing of three amplicons identified two molecular variants, with exon 4 of WWTR1 being fused in-
frame to either exon 8 (variant 1, upper panel) or exon 9 (variant 2, lower panel) of CAMTA1. (C) FISH demonstration of fused signals, 
using probes centromeric to CAMTA1 and telomeric to WWTR1. 
 
 
In terms of survival outcome, at follow-up, 9 patients were alive with no evidence of 
disease, 2 were alive with disease, 4 had died of disease, and 2 were lost to follow-up. 
None of the other vascular tumors (13 cases of epithelioid hemangioma, 5 of 
epithelioid angiosarcoma, and 3 of epithelioid sarcoma) had a WWTR1-CAMTA1 fusion. 
Two epithelioid hemangiomas of bone were excluded because of unsuccessful FISH due to 
decalcification. 
 
Discussion 
 
One of the most confusing issues related to vascular tumors is the myriad of names 
that are used to describe them. Pathologically, these tumors are remarkably similar, which 
makes differentiating them from each other very difficult (Wenger and Wold, 2000). This 
issue is compounded by the fact that current surgical pathology textbooks inadequately 
 11 
 
describe and classify these tumors. Moreover, most of these textbooks do not even 
acknowledge the existence of the 3 subtypes of epithelioid neoplasms. Not surprisingly, 
epithelioid hemangioma continues to be confused with EHE (O’Connell et al., 2001). In a 
series of 13 patients with so-called hemangioendothelioma reported by Evans et al. (2003), 3 
of their patients were treated with chemotherapy, and another 3 underwent amputation. 
However, none of the patients in their series died. Furthermore, Rosenberg has argued that 
Evans et al.’s illustrations of the tumors show characteristics of epithelioid hemangioma, a 
benign neoplasm (Floris et al., 2006). This example illustrates the danger inherent in using 
poorly defined and inappropriate terminology to classify vascular tumors. Because clinical 
behavior and, consequently, treatment and prognosis vary significantly among vascular 
tumors, it is important to effectively and accurately distinguish them from each other.  
Currently, we are limited to our subjective interpretations, so molecular analysis may 
help provide an objective answer. Prior to the current study, an identical chromosomal 
translocation [t(1;3)(p36.3:q25)] was identified in 2 cases of EHE arising in 2 distinct 
anatomic locations, the liver and soft tissue (Mendlick et al., 2001).  
In our study, an in-depth molecular analysis of 17 cases of EHE arising in different 
anatomic locations revealed an identical genetic translocation [t(1;3)(p36:q25)] involving the 
CAMTA1 and WWTR1 genes on chromosomes 1 and 3, respectively. As a result of the 
translocation, 2 protein-coding regions were fused in-frame, producing a chimeric protein. To 
our knowledge, this is the first time that a CAMTA1-WWTR1 fusion has been reported. This 
is especially important because the CAMTA1 and WWTR1 genes have been shown to play 
an important role in oncogenesis (Barbashina et al., 2005; Henrich et al., 2006; Lei et al., 
2008; Chan et al., 2009; Zhang et al., 2009). 
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CAMTA1 
CAMTA1 is a member of a recently described protein family designed as calmodulin-
binding transcription activators (CAMTAs) (Bouché et al., 2002). Its primary structure 
contains a nuclear localization signal, 2 DNA-binding domains (CG-1 and TIG), calmodulin-
binding motifs, and ankyrin repeats. CAMTA1 is a transcription activator potentially 
involved in cell cycle regulation (Nakatani et al., 2004) that may interact with 
Ca2+/calmodulin and be engaged in Ca2+ signaling (Bouché et al., 2002).  
In mammalian cells, Ca2+ and the Ca2+ receptor calmodulin are involved in the 
regulation of gene transcription; nuclear and cytoplasmic Ca2+ control transcription by 
distinct mechanisms. Indeed, certain transcription factors are selectively activated in response 
to distinct Ca2+ signal duration and amplitude (Bouché et al., 2002; Lipskaia and Lompré, 
2004; Munaron et al., 2006). A sustained increase in cytosolic Ca2+ is necessary to activate 
calcineurin, a Ca2+/calmodulin–dependent phosphatase, which dephosphorylates many 
proteins including the transcription factor NFAT (nuclear factor of activated cells) and 
induces its translocation to the nucleus (Lipskaia and Lompré, 2004; Munaron et al., 2006).  
By contrast, transient Ca2+ influx is particularly effective in activating CREB, the 
cAMP-responsive element binding protein, via Ca2+/calmodulin–dependent phosphorylation 
by Ca2+/calmodulin–dependent protein kinase (CaMK) or by mitogen-activated protein 
kinase (Lipskaia and Lompré, 2004; Munaron et al., 2006). Phosphorylation of CREB by 
Ca2+ facilitates its interaction with the co-activator CREB-binding protein (CBP) or the 
related protein p300. There is substantial evidence suggesting that the p300/CBP 
transcriptional co-activators play a critical role in the transactivation of the tumor suppressor 
p53 and on downstream effects of p53 on growth arrest and apoptosis. Therefore, one of the 
functions of CREB phosphorylation via Ca2+ entry might be the maintenance of a quiescent  
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state, at least in excitable cells (Lipskaia and Lompré, 2004; Finkler et al., 2007).  
A possible correlation between CAMTA1 and growth control is further supported by 
Nakatani et al. (2004), who examined the expression of CAMTA1 mRNA and protein during 
cell cycle progression in human neuroblastoma cells. Because the expression of CAMTA1 
was found to be similar to that of p53 in neuroblastoma cell lines, they speculated that 
CAMTA could be involved in cell cycle regulation in the same way as p53 (Nakatani et al., 
2004).  
Bouché et al. (2002) investigated the properties of members of the CAMTA family 
from Arabidopsis and humans and demonstrated the ability of both to interact with DNA in 
vitro and activate transcription in yeast cells. Using the fly CAMTA, Gong et al. (2007) 
further demonstrated that CAMTAs may function as a dimer, both in vitro and in fly 
photoreceptor neurons, and that the CG-1 domain may mediate the potential dimerization of 
CAMTA transcription factors. Therefore, in organisms with multiple CAMTAs, the 
possibility of homo- and heterodimerization exists with further functional implications 
(Finkler et al., 2007; Gong et al., 2007). 
  A possible role for human CAMTA1 in cell proliferation and tumor suppression has 
recently been put forward by several research groups (Katoh and Katoh, 2003; Attiyeh et al., 
2005; Barbashina et al., 2005; Henrich et al., 2006).  
Loss of genetic material on the short arm of chromosome 1 occurs in many human 
cancers. In a study of 683 solid tumors arising at different anatomic locations, the prevalence 
of loss of heterozygosity on 1p ranged from 30% to 64%, depending on tumor location 
(Ragnarsson et al., 1999). However, the most extensive 1p deletion mapping in search of 
tumor suppressors has been done in neuroblastomas, which are known to have 1p losses in 
about 30% of cases (Maris et al., 2000; Attiyeh et al., 2005; White et al., 2005).  
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Although the expression of CAMTA1 is seen in various organs, low CAMTA1 
expression seems to be significantly associated with poor outcome in neuroblastoma (Attiyeh 
et al., 2005; Henrich et al., 2006). In addition, Katoh and Katoh (2003) showed that the 
CAMTA1 gene was located within the commonly deleted region of neuroblastoma. The 
potential role of CAMTA1 in tumor development is also supported by Barbashina et al. 
(2005) who showed, in a subset of gliomas, that a deleted region on 1p36 involved the 
CAMTA1 gene.  
Taken together, these data strongly suggest that CAMTA1 is involved in the 
development of neuroblastoma and other tumors with 1p mutations. Identifying CAMTA1 
downstream target genes and interacting proteins are among the major tasks ahead. Such 
studies should provide important information to elucidate the role of CAMTA1 in 
oncogenesis and, consequently, improve diagnostic tools and therapies. 
 
WWTR1 
WWTR1, also called TAZ, is a transcriptional co-activator with PDZ-binding motif 
that was initially identified by its ability to interact with 14-3-3 proteins. Sharing amino acid 
sequence homology with YAP (Yes-associated protein), TAZ contains a conserved WW 
domain capable to interact with the PDZ domain (Kanai et al., 2000). Lei et al. (2008) 
reported that TAZ is negatively regulated by LATS tumor suppressor kinase, which is a 
component of the Hippo pathway initially defined by genetic studies in Drosophila 
melanogaster (Justice et al., 1995; Xu et al., 1995; Tapon et al., 2002).  
The Hippo pathway controls organ size and contact inhibition by regulating cell 
proliferation and apoptosis (Chan et al., 2010a). It is conserved from fly to human and its 
deregulation in mammals often leads to tumorigenesis (Chan et al., 2010a). The downstream 
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effectors of the Hippo pathway in mammals are the transcriptional co-activators YAP and 
TAZ.  
The transcription factors TEAD1-4 (TEADs) in mammals are major interacting 
partners for functional outcome. When TAZ is not inhibited by the Hippo pathway and 
remains in the nucleus, it interacts with TEADs and activates expression of genes such as 
CTGF, IGFBP3, ITGB2, Birc5/Survivin, Gli2, and Axl (Chan et al., 2010a). Phosphorylation 
of TAZ by LATS leads to 14-3-3 binding and translocation from the nucleus to the cytoplasm, 
resulting in functional inactivation of this transcription co-activator. TAZ itself has no DNA-
binding domain, and so it must bind to DNA-binding transcription factors to stimulate 
downstream target gene expression (Lei et al., 2008).  
TAZ has been shown to interact not only with TEADs (Chan et al., 2009) but also 
with many other proteins, such as EphrinB1 (Xing et al., 2010), Cbfa1/Runx2 (Hong et al., 
2005), Wbp2 (Chan et al., 2010b), and PAX3 (Marukami et al., 2005). The identification of a 
myriad of TAZ-interacting transcription factors participating in various cellular and 
development processes raises an important question as to which protein is most relevant to 
the role of TAZ in oncogenesis and what is the underlying molecular mechanism (Chan et al., 
2009).  
Chan et al. (2009) presented evidence supporting a novel mechanism for TEADs to 
mediate nuclear accumulation of TAZ to promote oncogenic transformation. They suggested 
that TAZ distribution is regulated by 2 major regulatory mechanisms. The first is the well-
defined cytoplasmic sequestration by interaction with 14-3-3 proteins upon its 
phosphorylation by the Hippo pathway; the other is nuclear retention mediated by its 
interaction with TEADs. Their results suggest that endogenous TEADs, and especially 
TEAD4, are important for TAZ to promote oncogenic transformation of MCF10A cells 
(Chan et al., 2009).  
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Zhang et al. (2009) supported these results and identified TEADs transcription factors 
as the major TAZ-interacting transcription factors in HEK293 cells. They further 
demonstrated that TEADs are indispensable for TAZ function in promoting cell proliferation 
and cell migration and in inducing epithelial mesenchymal transition, which are all involved 
in cancer initiation and progression (Zhang et al., 2009).  
TAZ is highly expressed in a wide spectrum of human cancer cell lines and various 
primary tumors, suggesting that this protein has oncogenic potential (Chan et al., 2008; 
Balasenthil et al., 2010). Chan et al. (2008) reported that TAZ was highly expressed in 
invasive breast cancer cell lines and in a significant fraction of primary breast cancers. They 
also reported that TAZ overexpression induced morphologic changes characteristic of cell 
transformation and enhanced cell migration and invasion (Chan et al., 2008).  
In addition, Balasenthil et al. (2010) found TAZ overexpression in pancreatic cell 
lines. Ectopic TAZ expression also induced cell proliferation, overcame contact inhibition, 
and led to tumorigenesis in nude mice (Lei et al., 2008).  
Taken together, these finding advance our understanding of the role of TAZ in cancer 
development and provide a potential therapeutic target for cancer treatment. Chan et al. 
(2011) recently showed that angiomotin, a novel regulator of endothelial cell migration 
(Troyanovsky et al., 2001), can interact with TAZ, leading to its cytoplasmic retention and 
inhibiting its transcriptional outcome and oncogenic property. This interaction causes 
cytoplasmic sequestration of TAZ in a manner similar to, but independent of, TAZ 
interaction with the Hippo pathway. Along with this study, future experiments should further 
our understanding of the possible use of angiomotin as a targeted therapy for EHE. 
Acquired chromosome abnormalities were first suggested to be casual factors in the 
origin of cancer by Boveri in 1902 (Boveri, 2008). However, the first specific translocation 
identified in human neoplasia was t(9;22)(q34;q11), resulting in the Philadelphia 
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chromosome (Rowley JD, 1973).  There is now a general agreement that cancer is a genetic 
disease with 2 types of initiating genetic events having been identified: the inactivation of 
genes by deletion, mutation, or epigenetic mechanism, and the activation or deregulation of 
genes as a consequence of point mutation, amplification, or balance cytogenetic 
abnormalities (Mitelman F et al., 2007). It is also should be noted that there are a few 
examples of balanced translocations leading to a loss of gene function (Popovici et al., 2002; 
Belloni et al., 2004).  
Compared with haematological disorders, our knowledge of the karyotype of solid 
tumors is limited. All solid tumors make up only 27% of the total number of cases with an 
abnormal karyotype reported in the literature (Mitelman F et al., 2007). In fact, we know less 
about cytogenetics of the most common malignant tumors becasuse the chromosome 
morphology is often poor and the karyoptype is usually complex. However, molecular and 
cytogenetic studies performed over the past decades have had a major impact on the 
identification and classification of a large variety of sarcomas (Bovée and Hogendoorn, 2010).  
Non-random chromosomal translocations have been detected in about 15% to 20% of 
mesenchymal tumors, and they are restricted to specific tumor types (Mitelman et al., 2007; 
Bovée and Hogendoorn, 2010). Tumor specific molecular changes can be useful for several 
reasons. First, the identification of chromosomal translocations helps the pathologist in 
diagnosing these lesions. Second, these tumor-specific molecular changes may serve as 
markers to detect minimal residual disease. Third, these molecular data increase our 
understanding of the pathogenesis of cancer. Finally, recurrent fusion oncogenes offer the 
best potential targets for therapeutics strategies (Kaye, 2009; Bovée and Hogendoorn, 2010).  
Since vascular tumors are uncommon neoplasms, they are generally regarded as 
difficult to classify by surgical pathologists. The differential diagnosis of these tumors can be 
very difficult because of their remarkably similar histopathologic and morphologic features. 
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Although morphologic and immunohistochemical features remain the cornerstone of 
diagnosis, tumor-specific genetic alterations can be very helpful in diagnosis-making (Bovée 
JV and Hogendoorn PC, 2010). Indeed, there is a strong sentiment to reclassify solid tumors 
on the basis of their pathogenetic fusion translocations (Kaye, 2009).  
It is important to emphasize that the rearrangenets might not be the sole anomaly. In 
fact, tumor developmemt is usually clonal evolution process driven by the accumulation of 
new genetic changes. However, recurrent balanced aberrations represent often an initial event 
in oncogenesis. Moreover, there is some evidence that the expression of certain sarcoma gene 
fusions is sufficient for the cell differentiation and tumorigenicity (Riggi et al. 2006; Riggi et 
al 2010).  
Most balanced structural rearrangements have been found to exert their tumorigenic 
action by 2 alternative mechanisms: overexpression of a gene in one of the breakpoints, or the 
creation of a hybrid gene through the fusion of two genes, one in each breakpoint. Therefore, 
the identification of structural chromosome changes is important because the breakpoints 
involved point to the location of cancer-relevant genes (Mitelman et al., 2007). Specific 
translocations can also reveal targets for therapy. A fusion product involving the collagen 
type 1, α1 gene and the platelet-derived growth factor B gene (COL1A1-PDGFB) in 
dermatofibrosarcoma protuberans can be blocked using tyrosine kinase inhibitors at PDGFR, 
such as imatinib (Bovée and Hogendoorn, 2010). 
In summary, we identified a novel specific chromosomal translocation 
[t(1;3)(p36:q25)] in 17 cases of EHE arising in distinct anatomic locations and involving the 
CAMTA1 and WWTR1 genes. This chromosomal translocation may serve as the ultimate 
biomarker, as it is specific for this distinct histopathologic tumor type, so it may be helpful to 
refine the classification of vascular neoplasms.   
Furthermore, it is widely accepted that fusion proteins resulting from chromosome 
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translocations are oncogenic, based on evidence that they are able to transform cells in 
culture (Xia and Barr, 2005). As more oncogenic properties of the fusion protein and 
cooperative events are elucidated, therapeutic strategies can be further developed to interrupt 
these oncogenic processes.  
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Chapter 2 
Monoclonality of multifocal epithelioid hemangioendothelioma: confirmation by analysis of 
WWTR1-CAMTA1 rearrangements. 
 
 
Introduction 
 
Epithelioid haemangioendothelioma (EHE), similar to other vascular tumors, presents 
with multiple non-contiguous tumors in approximately 50% of cases, and it is unclear 
whether the separate lesions represent multicentric disease or metastases (Deyrup and 
Montag, 2007; O’Connell et al., 2001). Multicentricity in mesenchymal neoplasms is defined 
the presence of tumor at two or more anatomically separated sites, before the manifestation of 
disease in sites where sarcomas most commonly metastasize, such as the lungs (Antonescu et 
al., 2000). Because the clinical course of EHE is frequently indolent, the concept that 
different lesions are independent primary tumors often prevails (Gupta et al., 2006; 
O’Connell et al., 2001).  
However, it seems that we are limited to our subjective interpretations and that we 
must wait for molecular analysis of vascular tumors before a more definitive and objective 
answer becomes apparent. 
In this study, we examined the question of whether EHE is a metastatic or 
multicentric disease. The recent identification of WWTR1-CAMTA1 fusion, as the genetic 
hallmark of EHE irrespective of anatomic location, provides an objective and powerful 
diagnostic tool that can be used to distinguish if multifocal EHE has a monoclonal origin. In 
fact, as expected, in our previous study the genomic breakpoints of the t(1;3)(p36;q25) 
differed from one patient to others (Errani et al., 2011). 
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Therefore, we undertook a molecular analysis of 2 multicentric EHEs of the liver, 
including separate tumor samples from each patient. Our hypothesis is that the identification 
of an identical WWTR1-CAMTA1 rearrangement in different lesions from each patient could 
explain the monoclonal origin of EHE. 
 
Material and Methods 
 
We retrieved 2 cases of EHE from the surgical pathology files of our institution with 
available tissue for molecular analysis. In each case, the diagnosis and histologic grade was 
confirmed by reviewing the H&E slides. All tumors included for analysis were positive for 
the CD31 endothelial marker. The tumors were assessed morphologically for growth pattern, 
vasoformative nature, epithelioid versus spindle cell composition, cellular pleomorphism, 
mitotic activity, and necrosis (Fig. 1).  
For each case, the location of the tumor was recorded, along with the anatomic 
structures involved. Both patients presented with multiple sites in the liver, two lesions and 
three lesions, respectively (Fig. 2).  
Fluorescence in situ hybridization (FISH) positional cloning of the t(1;3)(1p36.23;3q25.1).  
FISH was performed in both cases for the presence of WWTR1/CAMTA1 
rearrangement to confirm the histologic diagnosis (Errani et al., 2011).  
As previously reported, BAC clones were obtained from the BACPAC Resources 
Center of the Children’s Hospital of Oakland Research Institute (http://bacpac.chori.org) 
(Errani et al., 2011). Probe preparation and FISH analysis were performed on paraffin-
embedded, 4-µm-thick tissue sections, as previously described (Antonescu et al., 2010).  
In brief, BAC DNA was isolated using phenol-chloroform, labeled with different 
fluorochromes (Enzo, PA, USA) in a nick translation reaction, and validated on normal 
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metaphases. Probe mixtures were co-denatured, and hybridized to pretreated slides. Slides 
were incubated, washed and mounted with DAPI in an antifade solution. At least two 
hundred successive non-overlapping nuclei were examined using a fluorescence microscope.  
A case was confirmed as positive for rearrangement of a given gene when ≥ 20% of 
the nuclei examined showed a break-apart signal pattern using its respective BAC probes. 
Reverse transcriptase-polymerase chain reaction (RT-PCR).  
In both EHE tumors adequate RNA extracted from frozen tissue (Trizol Reagent; 
Invitrogen, USA) was available to investigate possible fusion transcripts from each different 
lesion in each patient. RNA quality was determined by Eukaryote Total RNA Nano Assay 
and cDNA was tested by RT-PCR for PGK housekeeping gene. A two-step RT-PCR was 
used, with Oligo(dT)20 primer under SuperScript® III system (Invitrogen, USA) being 
applied for first-strand cDNA synthesis, followed by a second-step PCR, using the HotStar 
Taq Master Mix (Qiagen, Valencia, CA). The RT-PCR products were analyzed by 
electrophoresis and the RT-PCR amplified products were sequenced using the Sanger method. 
Primers used for the RT-PCR detection of WWTR1-CAMTA1 fusion are listed in Table 1.  
 
Results 
 
FISH analysis for the presence of a WWTR1 and CAMTA1 gene rearrangements 
showed signal abnormalities in both WWTR1 and CAMTA1. Combined results confirmed the 
translocation t(1;3)(1p36.23;3q25.1) in both EHE cases (Fig. 3). 
The RT-PCR applied in both cases identified an amplified product in each case, but of 
two different sizes. However, the size of the rearranged bands from multifocal tumors in each 
individual patient was identical (Fig. 4). RT-PCR amplified two 5’WWTR1-CAMTA13’ 
variant transcripts from both EHE cases. The 5’WWTR1 showed a consistent breakpoint 
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within intron 3 and intron 4 respectively, while another 2 different breakpoints were seen in 
exon 9 by 3’CAMTA1. Exon 3 (variant 1) and exon 4 (variant 2) of WWTR1 were fused to 
CAMTA1 exon 9. 
The sequence of the fusion gene confirmed a different WWTR1-CAMTA1 
rearrangement in each patient, but an identical WWTR1-CAMTA1 rearrangement from 
different lesions in each individual patient (Fig. 5). 
 
 
Fig. 5: Gel electrophoresis showing amplified products from two different cases of two distinct sizes. 
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Fig 6: Sequencing of three amplicons identified two molecular variants, with exon 3 (variant 1, upper panel) or exon 4(variant 2, lower 
panel) of WWTR1 being fused in-frame to exon 9  of CAMTA1. 
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Discussion 
 
As with other vascular tumors, epithelioid hemangioendotelioma can be multifocal in 
up to 50% of cases (Deyrup and Montag, 2007; O’Connell et al., 2001). Because of its usual 
indolent clinical behaviour, this finding is commonly referred to as multifocal disease, and is 
often not accepted or recognised as a metastatic process (Gupta et al., 2006; O’Connell et al., 
2001). 
In this study, we examined the question of whether EHE is a multicentric or 
metastatic tumor. We hypothesized that molecular analysis could help elucidate this question. 
A variety of molecular genetic molecular techniques can be utilized to determine the 
clonality of multifocal tumors. Monoclonal tumors should exhibit the identical initial genetic 
alteration in genes responsible for early tumor development. However, additional genetic 
changes will subsequently accumulate, leading to sub-clonal divergence and intratumoral 
heterogenicity (Hafner et al., 2002).  
A frequent used method for evaluating clonality is based on X-chromosome 
inactivation. However, the reliability of X-chromosome inactivation analysis for clonality 
study in tumors has been challenged (Sieben et al., 2003). One problem is that tumors may 
show altered DNA methylation patterns. Furthermore, non-random X-chromosome 
inactivation in germline DNA of healthy and cancer-affected females may complicate the 
interpretation (Sieben et al., 2003). 
In contrast to analysis of clonality by X-chromosome inactivation, loss of 
heterozygosity (LOH) is an irreversible genetic event acquired during tumorigenesis rather 
than an epigenetic phenomenon like methylation. The weakness of this approach is that in the 
absence of informative markers and the failure to detect LOH it is likely to underestimate the 
frequency of clonality (Sieben et al., 2003).  
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Another technique used to investigate clonality in multifocal cancer is comparative 
genomic hybridization (CGH). However, in contrast to LOH analysis, the alternate loss of 
paternal and maternal alleles, strongly indicating different clones, is not detectable with this 
method. Therefore, CGH and LOH analysis may be less sensitive methods for detecting 
genetic aberrations as compared to polymerase chain reaction (PCR) (Kros et al., 2002).  
If the gene rearrangement is the initiating event of tumorigenesis, fusion product 
seems to be the most powerful idiotypic clonal marker (Antonescu et al., 2000; Melotti et al., 
2010).  In chromosomal translocations, the genomic breakpoints usually occur within introns. 
However, like in our study, the gene rearrangement can also occur within exons. Within 
introns or exons, the distribution of breakpoints from different cases seems essentially 
random. This provides formal support for the use of these rearrangements to establish clonal 
relationships in multifocal tumors characterized by specific chromosomal translocations 
(Antonescu et al., 2000). 
To our knowledge, there are only a few reports that have been used gene 
rearrangements to prove the clonal origin of multifocal tumor (Antonescu et al., 2000; 
Melotti et al., 2010; Ohta K et al., 2008; Plaza JA et al., 2008; Shah ZH et al., 2009; Sugg et 
al., 1998). Most of them have investigated multifocal lymphoproliferative processes and the 
analysis of clonality by PCR has played an important diagnostic role (Melotti et al., 2010; 
Ohta K et al., 2008; Plaza JA et al., 2008; Shah ZH et al., 2009; Sugg et al., 1998). Ohta et al. 
reported a case in which B cell monoclonality was found in an intraocular lymphoma and a 
primary breast lymphoma. They showed an identical gene rearrangement in the vitreous and 
breast tumors. The same-sized band were detected in both samples and direct sequencing of 
the PCR products revealed an identical monoclonal rearrangments of the IgH gene. 
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Our study shows similar result. In fact, we tested two multifocal liver EHEs with 
different rearrangments of WWTR1 and CAMTA1 genes. An identical monoclonal 
rearrangment was found in each lesion fron each patient, but not in tumors from different 
patients. The identical WWTR1-CAMTA1 rearrangment suggests that multifocal EHE 
resulted from metastasis of the same neoplastic clone rather than a simultaneous neoplastic 
formation of multiple EHE cell clones. 
Our conclusions are supported by the results of a recent study that reported a series of 
patients with liver EHE. Sixsteen patients received liver transplant and 5 of them (31%) had 
recurrence of disease in the new liver (Lau et al., 2011).  
This finding follows the “seed and soil” theory that Paget (1989) proposed in 1889, 
namely, “When a plant goes to seed, its seeds are carried in all directions; but they can only 
live and grow if they fall on congenial soil.”  
Recently, many investigators have validated this metastatic theory (Kaplan et al., 
2006; Gupta et al., 2006; Norton and Massagué, 2006). They defined the metastatic niche 
(soil) as a friendly site for the tumor cell (seed) to attach to and grow. In addition, Norton and 
Massagué (2006) proposed that cancer was a self-seeding disease and that the appearance of 
multifocality was conveyed by self-seeds returning to the primary tumor’s organ of origin but 
not attaching to the primary tumor mass.  
Following these hypotheses, we can speculate that in both our cases the EHE cells 
were able to attach and grow only in the liver. Therefore, it seems that multifocal EHE is 
more likely a metastatic disease rather than manifestation of multicentricity. 
Our data could have therapeutic implications. In fact, metastatic disease suggests an 
aggressive tumor that warrants further treatment; in contrast, tumors arising independently 
may simply reflect the propensity of an organ to develop occult tumors, which may or may 
not progress to clinically significant disease.  
 28 
 
In summary, our present analysis of the genomic rearrangments of WWTR1-
CAMTA1 genes in 2 patients with liver EHE confirms the monoclonal origin of multifocal 
EHE. This unusual clinical manifestation most likely represents an intrinsic property of this 
subset of EHE to re-seed in a congenial soil like the tissue of origin. 
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Chapter 3 
Epithelioid Hemangioma of Bone and Soft Tissue: a benign tumor with metastatic potential? 
 
 
Introduction 
 
Vascular tumors encompass a wide histologic spectrum and include hemangioma, 
hemangioendothelioma, angiosarcoma, and their epithelioid variants (Wenger and Wold,  
2000; O’Connell et al., 2001). The vast majority of both benign and malignant vascular 
tumors are readily diagnosed based on their characteristic histologic features, such as the 
formation of vascular spaces and the expression of endothelial markers. However, some 
vascular tumors have atypical histologic features, such as a solid growth pattern, epithelioid 
change, or spindle cell morphology, which complicates their diagnosis (Folpe et al., 2001).  
For this rare subset of vascular tumors, there remains considerable controversy in 
regards to the terminology and the classification that should be used (O’Connell et al., 2001; 
Evans et al., 2003). For instance, epithelioid hemangioma (EH) continues to be confused with 
hemangioendothelioma (O’Connell et al., 2001). Evans et al. (2003) recently argued that EH 
is not a distinct clinicopathologic entity but rather a misdiagnosed hemangioendothelioma, a 
tumor that, unlike hemangioma, has malignant potential. In a series of 13 patients with so-
called hemangioendothelioma reported by Evans et al. (2003), 3 of patients were treated with 
chemotherapy, and another 3 underwent amputation. Remarkably, none of the patients in 
their series died.  However, in a “Letter to the Editor” in the International Journal of Surgical 
Pathology, Rosenberg argued that Evans et al.’s illustrations of the tumors showed 
characteristics of EH, a benign neoplasm (Floris et al., 2006). This example not only 
illustrates the current confusion surrounding the classification of this rare subset of vascular 
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tumors but also indicates the danger inherent in using poorly defined and inappropriate 
terminology to classify them.  
Because the clinical behavior and, consequently, treatment and prognosis of vascular 
tumors can vary significantly, it is important to effectively and accurately distinguish them 
from each other.  In this study, we examined the question of whether EH is a benign tumor 
with metastatic potential. We hypothesize that the clinical behavior of EH can help elucidate 
this question and establish if this rare tumor is a benign or malignant neoplasm.  
 
Material and Methods 
 
We performed a retrospective analysis of all cases of EH from the surgical pathology 
files of our institution. In each case, the diagnosis of EH was confirmed by reviewing 
available histologic slides (Fig. 7).  
Available radiographic images were also reviewed, and treatment and follow-up 
information was obtained from the patient records. In addition, for each case, fluorescence in 
situ hybridization (FISH) was performed to exclude the presence of the specific chromosomal 
rearrangement t(1;3)(1p36.23;3q25.1), which has been shown to be characteristic of 
epithelioid hemangioendothelioma (EHE) (Errani et al., in press). BAC clones were selected 
according to the UCSC genome browser (http://genome.ucsc.edu) and were obtained from 
the BACPAC Resources Center of the Children’s Hospital of Oakland Research Institute 
(CHORI) (Oakland, CA) (http://bacpac.chori.org). Probe preparation and FISH analysis were 
performed on paraffin-embedded, 4-µm-thick tissue sections, as previously described 
(Antonescu et al., 2010).   
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Fig. 7: Histologic analysis showed (A) a lobular growth pattern of the lesion with extension outside the cortex in adjacent soft 
tissue; (B) mature vascular lumen formation with eosinophilis infiltrating the adjacent stroma; (C) vasoformative properties at the periphery 
of the lesion, with larger calibre vessels lined by epithelioid cells; (D) hobnailed endothelial cells protruding in the lumen in a characteristic 
tomstone appearance; (E) the central portion of the lesion typically had more solid growth with sheets of epithelioid cells with densely 
eosinophilic cytoplasm and lacked obvious vessel formation. Occasionally abundant erythrocyte extravasation was seen; (F) epithelioid cells 
with a more foamy, vacuolated cytoplasm and focal, moderate pleomorphism and pseudonuclear inclusions; (G) intracytoplasmic vacuoles 
but typically these were not a predominant feature; (H)occasional areas of bland spindle cell component; and (I) vascular ivasion in one 
patient who had lymphonode spread. 
 
 
At least 200 successive non-overlapping nuclei were examined using a fluorescence 
microscope. A case was considered to have a specific genetic rearrangement if ≥ 20% of the 
nuclei examined showed a break-apart signal pattern using its respective BAC probes (Fig. 8).  
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Fig. 8: Three-color fluorescence in situ hybridization (FISH) shows no break-apart (split signal) in the region of 3q25.1-25.3. 
 
Results 
 
We identified 16 patients with tissue available for molecular analysis: 4 women and 
12 men, with a mean age at presentation of 44 years (range, 18 to 81 years). Additional 
demographic data for these patients are shown in the Table. 
In each case, the diagnosis of EH was first confirmed by reviewing available 
histologic slides. All tumors were positive for the CD31 endothelial marker.  
Morphologically, EHs were defined as either lobulated or well-circumscribed lesions, which 
had clear vasoformative properties, forming “mature” vessels with open lumina. The lesional 
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cells occasionally had the so-called tombstone appearance and consistently showed an 
abundant, glassy, eosinophilic cytoplasm.  
The correct diagnosis of all our EH cases based on immunophenotype alone was 
confirmed thanks to lack of the specific genetic rearrangement [t(1;3)(1p36.23;3q25.1)] 
characteristic of epithelioid hemangioendothelioma that we showed in a previously report 
(Errani et al., 2011). 
The anatomic distribution of EH was as follows: 9 cases in bone, 5 in soft tissue and 2 
in both bone and soft tissue. Four patients had an unusual multifocal presentation of EH in 
the hand, wrist, foot, head and neck respectively.  
On conventional x-rays, the bone lesions were usually lucent with well-defined 
margins (Fig. 9).   
 
Fig 9: (A) The en bloc resection specimen shows a diffusely hemorrhagic cut surface lesion expanding the rib. (B) A contrast-enhanced CT 
image of the same patient shows a multiseptated, expansile lytic lesion in the anterior portion of the right ninth rib, indenting and causing 
low-attenuation presumed to be reactive edema in the subjacent liver. 
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In a few cases of EH of bone, the bone was expanded and focally destroyed with 
tumor extending into adjacent soft tissue. By contrast, in cases of EH of soft tissue, the 
lesions had less-defined margins on the magnetic resonance images.  The size of the tumors 
was known in 12 patients, ranging from 1 cm to 8.5 cm in diameter. 
Treatment varied widely, ranging from biopsy to segmental resection.  Most patients 
with EH of bone were treated with intralesional curettage. Three patients, 2 with EH in the rib 
and 1 with EH in the carpus, underwent segmental resection. By contrast, all patients with EH 
of soft tissue underwent excision with marginal or wide margins, except for 1 patient who 
only underwent biopsy. Two patients were also treated with radiation therapy, and one of 
these patients with systemic therapy.  
Follow-up information was available for all 16 patients; the mean follow-up time was 
64.5 months (range, 6 to 162 months). None of the patients died of disease, including the 4 
patients with a multifocal presentation of EH, and only 2 patients developed a local 
recurrence (Table 2). 
A few cases, because of their unusual clinical features, are described in detail.  The 
first patient was a 56-year-old woman with numerous lesions of the right foot (Fig 10). He 
was treated with trans-tarsal amputation. The patient is alive and well free of disease 66 
months later. The second patient was an 18-year-old man with an EH of the right carpus 
involving the scaphoid and trapezium bones. He underwent segmental resection with wide 
margins, and he is currently alive with no evidence of disease 156 months after surgery. The 
third patient was a 49-year-old man who presented with numerous bone and soft tissue EHs 
in the index and middle fingers.   
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EHCase 
no. 
Age 
(y) 
Sex Location Multifocal vs 
Solitary 
Treatment Outcome 
(months) 
1 63 M Soft Tissue (arm) Solitary Biopsy AWD 
(64) 
2 38 M Soft Tissue (arm) Solitary Surgery (M) NED (58) 
3 63 F Soft Tissue (hand) Solitary Surgery (M) NED (67) 
4 38 F Soft Tissue (axilla) Solitary Surgery (W) NED 
(162) 
5 31 M Bone (metatarsus) Solitary Surgery (I) NED (51) 
6 20 M Bone (metatarsus) Solitary Surgery (I) NED (31) 
7 40 M Bone (metatarsus) Solitary Surgery (I) NED1 
(22) 
7 59 M Bone (cuneiform) Solitary Surgery (I) NED (9) 
8 23 M Bone (rib) Solitary Surgery (W) NED (68) 
9 41 M Bone (rib) Solitary Surgery (W) NED1 
(67) 
10 81 M Bone (clavicle) Solitary Surgery (I) NED (6) 
11 50 M Bone (vertebra) Solitary Surgery (I) 
and RXT 
DOO (16) 
12 34 F Bone (tibia) Solitary Surgery (I) NED1 
(114) 
13 18 M Bone (carpus) Multifocal 
(scaphoid and 
trapezium) 
Surgery (W) NED 
(156) 
15 49 M Bone  and Soft 
Tissue (hand) 
Multifocal (index 
and middle 
fingers) 
Surgery (I) NED (48) 
16 56 F Bone and Soft 
Tissue (foot) 
Multifocal 
(midfoot and 
forefoot) 
Surgery (W) NED (66) 
17 35 M Soft Tissue (head 
and neck) 
Multifocal (bone 
and parotid) 
Surgery (M), 
RXT and CHT 
NED1 
(240) 
 
Table II: EH, epithelioid hemangioma; M, male; F, female; NED, no evidence of disease; NED1, no evidence of disease after local or distant 
recurrence; AWD, alive with disease; DOO, dead of other causes. 
 
Several lesions were excised, and the remainder was treated with laser therapy. This 
patient is alive and disease-free 48 months after treatment. Another patient was a 35-year-old 
man, who presented with a facial mass in 1991. He was treated with chemotherapy 
(Adriamycin and Edatrexate) without significance response. Therefore, he received 3000cGy 
in 10 fractions to the whole brain with an excellent response. He developed a local recurrence 
involving lymphoid tissue adjacent to the salivary gland in 2002.  
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Thus, the patient underwent marginal excision of the lesion followed by radiation 
therapy (4500cGy). He did well until 2005, when he presented left sphenoid and orbital roof 
metastases. These lesions were excised only in 2011 and the presence of EH was 
subsequently confirmed. He is alive 20 years later the first appearance of the disease.  
   
 
Fig 10: (A) A radiograph shows the first metatarsal has been replaced and expanded by a multiseptated lytic lesion. No gross calcified 
matrix is evident in the lesion. (B) A coronal non contrast CT image through the forefoot of the same patient shows marked expansion of the 
first metatarsal with extensive cortical destruction and several thin intralesional septa. The attenuation of the tumor is slightly lower than that 
of muscle. 
 
 
 
 
Finally, the last interesting case was that of a 63-year-old man diagnosed with a soft 
tissue EH in the arm (Fig 11). He was treated with biopsy alone and did not show any disease 
progression at follow-up 64 month after treatment. 
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Fig 11: (A) The radiograph shows a tiny permeative, lytic focus in the posterior cortex of the midhumeral shaft (arrow). No calcifications 
are evident in nearby soft tissues. (B) An axial proton density MR image shows heterogeneous tumor deposits in the triceps muscle and an 
intracortical tumor deposit (arrow). (C) A sagittal proton density MR image shows multinodular tumor deposits with low-signal intensity 
inner rings (arrows), possibly related to hemosiderin deposition. 
 
 
Discussion 
 
Epithelioid vascular tumors remain controversial because of their unusual morphology, 
poorly understood histogenesis, and unpredictable biologic behavior (Keel et al., 1999). In 
fact, there is much debate involving certain vascular tumors that show an epithelioid 
phenotype and that share many of the same histologic features. This has resulted in the 
frequent misdiagnosis and inappropriate treatment of EH (Nielsen et al., 2009).  
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Although imaging is extremely helpful in the diagnosis of hemangioma and usually 
excludes the need for biopsy, it cannot be used effectively in the diagnosis of EH and other 
vascular tumors because these entities lack characteristic radiologic features (Gupta et al., 
2006; Shah et al., 2005). In fact, the presence of multifocal lesions may be the only clue 
indicating a diagnosis of a vascular tumor (Wenger and Wold,  2000). 
Morphologic and immunohistochemical features thus remain the cornerstone of 
diagnosis of vascular tumors and their epithelioid variants. The differential diagnosis of EH 
includes EHE and epithelioid angiosarcoma. Because of their epitheloid appearance, 
epithelioid vascular neoplasms may also be misdiagnosed as metastatic carcinoma. However, 
antibodies against certain vascular and endothelial antigens have been shown to be helpful in 
differentiating vascular tumors from metastatic carcinomas (Kleer et al., 1996). Furthermore, 
features that distinguish EH from epithelioid angiosarcoma include the absence of significant 
cytologic atypia, brisk mitotic activity, and necrosis and the presence of well-formed vessels 
(Deyrup et al., 2007). The more difficult distinction between EH and EHE could be made on 
the basis of our recent discovery of a novel genetic rearrangement that is specific to EHE, 
[t(1;3)(1p36.23;3q25.1)] (Errani et al., in press), which was not present in all cases of EH 
analyzed in the current study. The correct differential diagnosis between these 2 entities is 
critical because EHE exhibits a more aggressive clinical course than EH. It is also more 
frequently multifocal when occurring in bone (O’Connell et al., 1993). By contrast, the vast 
majority of bone EHs are solitary. However, up to 25% of bone EHs can affect the skeleton 
in a multifocal fashion (Sung et al., 2000; O’Connell et al., 2001; Deshpande et al., 2003).  
Moreover, Floris et al. (2006) reported a case of EH of the 2nd toe with secondary 
involvement of the ipsilateral inguinal, iliac, and paraortic lymph nodes. The groin lymph 
nodes were excised, and the presence of EH was subsequently confirmed.  
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This 2006 article by Floris et al. sparked a controversy reflected in an exchange of 
opinions in the form of “Letters to the Editor” in the International Journal of Surgical 
Pathology (Floris et al., 2006). In his letter, Evans reiterated his opinion that EH is not a 
distinct clinicopathologic entity but rather a misdiagnosed hemangioendothelioma, a tumor 
with malignant potential. However, in his own letter, Rosenberg argued that these neoplasms 
are histologically and biologically different from one another. In a series of 13 patients with 
so-called hemangioendothelioma reported by Evans et al. (2003), none of the patients died of 
disease and, in Rosenberg’s opinion, Evans et al.’s illustrations of the tumors show 
characteristics of EH. Of these 13 patients, 3 were treated with aggressive chemotherapy, and 
3 underwent a forequarter amputation, hip disarticulation, and internal hemipelvectomy, for 
what Rosenberg considers a benign neoplasm. Clearly, the classification of epithelioid 
vascular tumors remains a topic of considerable controversy as EH continues to be confused 
with EHE or some other type of vascular sarcomas.   
Crucial to the significance of this controversy is what effect, if any, the classification 
of these vascular tumors has on their treatment and prognosis (O’Connell et al., 2001). In a 
recent study, Nielsen et al. (2009) analyzed 50 cases of EH of bone. In their series, most 
patients presented with a single lesion, but 9 patients (18%) presented with lesions involving 
more than 1 bone. Two of the patients with multifocal EHs had discontinuous lesions of bone, 
skin, artery, and lymph node, but none of these patients with an unusual multifocal 
presentation of EH experienced an adverse outcome. Therefore, the nonaggressive behavior 
of EH reported in the literature (Evans et al., 2003; Floris et al., 2006; Nielsen et al., 2009) 
supports the hypothesis that this tumor is indeed benign.  
Despite the fact that our series is relatively small, our findings confirm that EH does 
not behave aggressively and thus is a benign tumor. In fact, although most patients received 
conservative treatment, including only biopsy in 1 case, their long-term prognosis was 
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excellent, and none of them died of disease. By contrast, as we previously reported, EHE is 
also associated with good prognosis, but it can metastasize in some cases and produce a fatal 
outcome (Errani et al., in press ).   
In the current study, we found that 4 cases of EH had a multifocal appearance. 
Although we cannot disprove a multicentric origin for EH, we favor the theory of metastatic 
spread of the tumor from bone and soft tissue, given the intimate relationship that vascular 
tumors typically have with non-neoplastic vessels (Bollinger et al., 1994).  However, we do 
not believe that metastatic potential necessarily means malignancy. In 1889, Paget (1989) 
originally proposed the “seed and soil” theory, namely, “When a plant goes to seed, its seeds 
are carried in all directions; but they can only live and grow if they fall on congenital soil.” 
Recently, many investigators have validated the metastatic theory (Kaplan et al., 2006; Gupta 
et al., 2006; Norton and Massagué, 2006). They defined the metastatic niche (soil) as a 
friendly site for the tumor cell (seed) to attach to and grow. In Kaplan et al.’s and Gupta et 
al.’s hypotheses, the metastatic niche is prepared by a substance secreted by the primary 
tumor. The metastatic niche contains precursor cells or bone marrow-derived stem cells. 
Subsequently, the invading metastatic cell must exhibit the proper features to effectively 
colonize the new site. Their data suggest that differences in tumor-secreted humoral factors 
promote metastatic spread to specific distant organs, and, as expected, the genes that mediate 
these different site-specific metastatic activities are largely distinct. In addition, Norton and 
Massagué (2006) proposed that cancer was a self-seeding disease and that the appearance of 
multifocality was conveyed by self-seeds returning to the primary tumor’s organ of origin but 
not attaching to the primary tumor mass.  
Building upon these hypotheses, Mihm and Nelson (2010) proposed that the 
metastatic niche theory can elucidate infantile hemangioma development.  They reported that 
infantile hemangiomas may be metastases from the fetal component of placenta. In fact, 
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certain aspects of the biology of infantile hemangioma cells suggest a relationship to the 
placenta as a possible site of origin for hemangioma precursor cells. First, distinct 
immunohistochemical markers are uniquely co-expressed by fetal microvessels of the human 
placenta and juvenile hemangiomas (North et al., 2001). Second, the genome-wide gene 
expression profiles of the placenta and hemangiomas exhibit a higher degree of global 
similarity relative to other tissues (Barnes et al., 2005). Finally, the natural progression of 
infantile hemangiomas is similar to that of the placenta (rapid proliferation followed by 
subsequent stabilization). Thus, they hypothesized that the site where hemangioma forms is 
prepared by humoral factors that determine the site of infantile hemangioma development, in 
the same way that malignant tumor cells prepare a site for tumor metastases (Mihm and 
Nelson, 2010). Taken together, these findings suggest that hemangioma precursor cell arise 
from the placenta as a “benign metastasis.”   
The possible existence of benign metastasis is further supported by the behavior of 
giant cell tumors, another type of benign bone tumor that can metastasize without producing 
a fatal outcome. At the Rizzoli Institute, the overall metastatic rate of 349 giant cell tumors of 
the extremity was 4%, and all tumors were associated with good long-term prognosis (Errani 
et al., 2010). Similarly, Klenke et al. (2011) found the same rate of pulmonary metastases in 
118 patients with giant cell tumors, and none of the patients died of disease. However, we 
ultimately agree with Rosenberg, who pointed out, “Currently, it seems that we are limited to 
our subjective interpretations and that we must wait for molecular analysis of vascular tumors 
before a more definitive and objective answer becomes apparent” (Floris et al., 2006).  
In summary, our findings confirm that EH does not behave aggressively and support 
the contention that EH is a benign tumor. Based on our experience, EH of bone can be 
effectively treated with curettage and EH of soft tissue with marginal/wide excision; EH is 
thus associated with an excellent prognosis. Like other vascular tumors, however, EH may 
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present with multifocal involvement. Therefore, we conclude that EH is a benign tumor with 
metastatic potential. It is important to distinguish EH from other epithelioid vascular tumors 
because of the significant differences in their management and clinical outcome. 
 
Conclusions 
 
The classification of epithelioid vascular tumors remains challenging with considerable 
morphologic overlap spanning across benign to malignant categories. A prior 
t(1;3)(p36.3;q25) was identified in 2 cases of EHE, however no follow-up studies have been 
performed to identify the gene fusion or to assess its prevalence in a larger cohort of patients. 
We undertook a systematic molecular analysis of 17 EHE, characterized by classic 
morphologic and immunophenotypic features, from various anatomic locations and with 
different malignant potential. Also included for comparison was a group of epithelioid 
hemangioma and epithelioid angiosarcoma. FISH positional cloning strategy, spanning the 
cytogenetically defined regions on chromosomes 1p36.3 and 3q25, confirmed rearrangements 
in two candidate genes from these loci in all EHE cases tested. Subsequent RT-PCR 
confirmed the CAMTA1-WWTR1 fusion product in 3 cases. None of the other benign or 
malignant epithelioid vascular tumors examined showed these abnormalities. CAMTA1 and 
WWTR1 genes have been previously shown to play important roles in oncogenesis. Our 
results demonstrate the presence of CAMTA1-WWTR1 fusion in all EHE tested from bone, 
soft tissue and visceral location (liver, lung) in keeping with a single tumor entity. Thus FISH 
or RT-PCR analysis for this fusion can serve as a useful molecular diagnostic tool in 
challenging diagnoses. 
Like other vascular tumors, EHE can have multifocal presentation in up to 50% of cases. 
However, whether multifocal EHE represents an unusual pattern of metastasis or multiple 
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separate primary tumors remains to be elucidated. Our recent identification of WWTR1-
CAMTA1 fusion as the genetic hallmark of EHE irrespective of anatomic location was used to 
clarify this question by comparing the similarity of translocation breakpoints. In our previous 
study, we found variability of the fusion transcripts of the t(1;3)(p36;q25) translocation 
among different patients with EHE. Thus, we undertook a molecular analysis of six samples 
from two patients with multicentric hepatic EHE to test our hypothesis that the presence of 
identical breakpoints in WWTR1 and CAMTA1 support the monoclonal nature of multifocal 
EHE. Using FISH, RT-PCR and subsequent sequencing we confirmed an identical WWTR1-
CAMTA1 fusion transcript product from different nodules in each patient. Our results confirm 
that multifocal EHE are monoclonal and thus representing metastatic implants of the same 
neoplastic clone rather than a ‘field-effect’ or synchronous occurrence of multiple neoplastic 
clones.  
The controversy surrounding EH diagnosis, particularly when arising in skeletal locations, 
stems not only from its overlapping features with other malignant vascular neoplasms, but 
also from its somewhat aggressive clinical characteristics, including multifocal presentation 
and occasional lymph node metastases. Specifically, the distinction from EHE has been 
considerably controversial. The recurrent t(1;3)(p36;q25) chromosomal translocation, 
resulting in WWTR1-CAMTA1 fusion, recently identified in EHE of various anatomic sites, 
but not in EH or other epithelioid vascular neoplasms, suggests distinct pathogeneses. Thus, 
we investigated the clinicopathologic and radiographic characteristics of bone and soft tissue 
EHs in patients treated at our Institution with available tissue for molecular testing. Seventeen 
patients were selected after confirming the pathologic diagnosis and FISH analysis for the 
WWTR1 and/or CAMTA1 rearrangements. Four patients had multifocal presentation, 
including one with locoregional lymph node metastases. Most patients with EH of bone were 
treated by intralesional curettings, while patients with EH of soft tissue underwent excision 
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with marginal or wide margins. None of the patients died of disease and only four patients 
developed a local recurrence. Our results, using molecular testing to support the pathologic 
diagnosis of EH, reinforce prior data that EH is a benign lesion, characterized by an indolent 
clinical course, with occasional multifocal presentation and rare metastatic potential to 
locoregional lymph nodes. These findings highlight the importance of distinguishing EH 
from other malignant epithelioid vascular tumors due to their difference in management and 
clinical outcome. 
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